PCDD/Fs and PCBs in hen eggs from a contaminated area in Italy: a 9 years spatio-temporal monitoring study.

Eggs can represent a food susceptible to contamination, with bioaccumulation potential for POPs. The Province of Taranto, Southern Italy, is of particular relevance in this context because of the presence of industrial sources of PCDD/Fs and PCBs. The aim of this study was to analyze and report the levels of these contaminants in hen eggs sampled in farms located within a radius of 20 km from the industrial area of Taranto. Between 2013 and 2021, 227 hen eggs were collected, according to a special monitoring plan of the Prevention Department. Samples were analyzed by the National Reference Laboratory for Halogenated POPs in Feed and Food. Median (IQR) values were: 0.28 (0.59) pg WHO-TEQ/g fat for PCDD/Fs, 0.89 (1.70) pg WHO-TEQ/g fat for PCDD/Fs + DL-PCBs, 0.57 (1.16) pg WHO-TEQ/g fat for DL-PCBs, 2.24 (5.51) ng/g fat for NDL-PCBs. Samples not-compliant (Reg. 1881/2006/EC and amendments) for at least one contaminant were 17 (7.5%). No contaminants values or exceedances showed a statistically significant correlation with distance from industrial area (p > 0.05). Higher PCDD/Fs values were observed in first and second quarters (p < 0.05). All contaminants' values pairwise combinations showed significant (p < 0.0001) strong (ρ > 0.7) correlation. According to our epidemiological investigations, the exceedances are to be attributed to factors mainly related to farmers' wrong habits. These results confirmed the importance of the monitoring of contaminants' levels in the matrices at risk as well as to focus on enhancing good management practices on eggs-producing farms.

Dioxins and PCBs contamination in milk and dairy products from Province of Taranto (Puglia Region, Southern Italy): a six years spatio-temporal monitoring study.

INTRODUCTION: Taranto Province (Puglia Region, Southern Italy) is of particular Public Health relevance due to the presence of industrial sources of dioxins and PCBs. The aim of this study was to analyze the spatio-temporal distribution of these pollutants in milk and cheese produced from 2013 to 2018. MATERIALS AND METHODS: Raw milk and dairy products were sampled in the farms located within 20 km from the industrial area. RESULTS: 1005 milk samples were collected. Median (IQR) concentrations were: dioxins 0.21 (0.21) pg WHO-TEQ/g fat; dioxins+DL-PCBs 0.83 (0.71) pg WHO-TEQ/g fat; NDL-PCBs 1.92 (1.56) ng/g fat. Overall, only 6 (0.6%) samples were found to be non-compliant for at least one pollutants group. Temporal analysis showed a decreasing trend in dioxins and PCBs concentrations over the observed years and higher values in the first trimester. Spatial analysis showed higher levels of PCBs in areas closest to the industrial pole. 70 dairy products samples were collected. Median pollutants concentrations were far below the EU limits and no exceedances were observed. CONCLUSIONS: The extremely low number of exceedances appeared as an encouraging result and supported the validity of the Public Health measures adopted by the Department of Prevention of Taranto.

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.

Background: We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls aged 9-14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D_M0,1,6) in women aged 15-25 years. Here, we report the results at study end (month 36 [M36]). Methods: Girls were randomized 1:1 and received 2 vaccine doses either 6 months (2D_M0,6) or 12 months apart (2D_M0,12); women received 3 doses at months 0, 1, and 6 (3D_M0,1,6). Endpoints included noninferiority of HPV-16/18 antibodies for 2D_M0,6 versus 3D_M0,1,6; 2D_M0,12 versus 3D_M0,1,6; and 2D_M0,12 versus 2D_M0,6; and assessment of neutralizing antibodies, T cells, B cells, and safety. Results: At M36, the 2D_M0,6 and 2D_M0,12 schedules remained noninferior to the 3D_M0,1,6 schedule in terms of seroconversion rates and 3D/2D geometric mean titers for anti-HPV-16 and anti-HPV-18. All schedules elicited sustained immune responses up to M36. Conclusions: Both 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study conclusion at M36. The AS04-HPV-16/18 vaccine administered as a 2-dose schedule was immunogenic and well tolerated in young girls.

The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.

INTRODUCTION: Multiple vaccination visits and administrations can be stressful for infants, parents and healthcare providers. Multivalent combination vaccines can deliver the required number of antigens in fewer injections and clinic visits, while vaccine co-administration can also reduce the number of visits. This non-inferiority study was undertaken to evaluate the feasibility of co-administering a combined measles-mumps-rubella-varicella (MMRV) vaccine with conjugated meningococcal C (MenC) vaccine in a large cohort of healthy Italian toddlers. METHODS: Healthy subjects aged 13-15months were randomized (2:1:1) to receive single doses of either: co-administered MMRV+MenC at the same visit (MMRV+MenC group); or MMRV followed 42days later by MenC (MMRV group); or MenC followed 42days later by MMRV (MenC group). Blood samples were collected before and 43days after vaccination. Antibody titers against MMRV were measured using ELISA. Functional-anti-meningococcal-serogroup activity (rSBAMenC) was assessed using a serum bactericidal test. Solicited local and general reactions were recorded for up to 4 and 42days post-vaccination, respectively. Non-inferiority of MMRV+MenC to MMRV (post-dose-1 seroconversion rates) and MMRV+MenC to MenC (post-dose-1 seroprotection rates) was achieved if the lower limit (LL) of the 95% confidence interval (CI) for the group difference was ⩾-10% for each antigen. RESULTS: 716 subjects were enrolled in the study. At 42days post-vaccination, the MMRV seroconversion rates were 99.3% (measles), 94.5% (mumps), 100% (rubella) and 99.7% (varicella) in the MMRV+MenC group, and 99.4%, 93.2%, 100% and 100%, respectively, in the MMRV group. The seroprotection rates against rSBA-MenC were 98.3% in the MMRV+MenC group and 99.3% in the MenC group. Non-inferiority was reached for all the vaccine antigens. The safety profiles were as expected for these vaccines. CONCLUSION: The immune responses elicited by co-administered MMRV+MenC were non-inferior to those elicited by MMRV or MenC alone and support vaccination of children with both vaccines at a single visit. CLINICAL TRIALS REGISTRATION: NCT01506193.

Vaccine co-administration in paediatric age: the experience of the Local Health Unit of Cuneo-1 (Ambito di Cuneo), Italy.

BACKGROUND AND AIM OF THE WORK: The immunization schedule might be continuously updated on the basis of the new scientific and epidemiological knowledge, possible changes in operational requirements and the availability of new products. A high vaccination compliance is strictly related to factors such as tolerability, effectiveness and number of injections. This last has always been a critical point and combined vaccines guarantee high levels of safety and immunogenicity requiring fewer injections and accesses to services. Co-administration should be considered in order to expand the supply of important vaccinations, (eg. meningococcal and pneumococcal), avoiding the increase of the number of accesses to services. METHODS: Since January 2007, an experience with the co-administration of hexavalent vaccine together with conjugate pneumococcal and meningococcal C vaccines started at the LHU CN1-Ambito di Cuneo. The target of this co-administration, based on scientific criteria, is to provide immunization against St. pneumoniae and N. meningitidis in newborns. RESULTS: Considering that the coverage rate (VC%) with hexavalent vaccine has been always high and that, at the end of 2006, the VC% for the pneumococcal and meningococcal C conjugate vaccines were equal to 50.4% and 44.4%, in this first year of experience the compliance to co-administration has significantly increased from 47% of doses administered in the first quarter of 2007 to 65% in the first quarter of 2008. CONCLUSIONS: Co-administration could be an useful mean to introduce new immunizations into the vaccination schedule and to achieve high vaccination coverage rates.